Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03313778
Title Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors ModernaTX, Inc.

Advanced Solid Tumor

bladder urothelial carcinoma

colorectal cancer

esophagus adenocarcinoma


gastric adenocarcinoma

endometrial cancer

lung non-small cell carcinoma

lung small cell carcinoma

head and neck squamous cell carcinoma


mRNA-4157 + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST